Relief therapeutics « Terug naar discussie overzicht

Relief therapeutics Holding

7.939 Posts, Pagina: « 1 2 3 4 5 6 ... 215 216 217 218 219 220 221 222 223 224 225 ... 393 394 395 396 397 » | Laatste
Seppie76
0
quote:

Bert-Jan schreef op 12 november 2020 14:40:


[...]

De MSCI is een index net zoals de AEX een index is. Relief wordt dus opgenomen in de MSCI Smal Cap Switzerland index. Beleggingsfondsen investeren vaak in dergelijke indexen vanwege risicospreiding. De opname van Relief in de index betekent dus dat iedereen die geïnvesteerd is in de index ook een stukje Relief koopt.

Dit heeft verder dus geen gevolgen voor jouw aandelen.


Thanx Bert-Jan! zou zonde zijn na 4 maanden van wachten en wachten en wachten als ik hierdoor alsnog een EAU/FDA goedkeuring mis zou lopen, hahaha.
TraceyH
0
En WEEEER gebeurd dit. Echt players zijn het! Zodra de 0.35 weer gehaald wordt, gaan ze er bij mij uit, DEFINITIEF!
Reader
1
evr68@hotmail.com
0
quote:

Reader schreef op 12 november 2020 17:33:


Erg jammer dit....gelukkig hebben we nog een dak boven ons hoofd ;-)


Humor!
MisterBlues
1
quote:

TraceyH schreef op 12 november 2020 17:16:


En WEEEER gebeurd dit. Echt players zijn het! Zodra de 0.35 weer gehaald wordt, gaan ze er bij mij uit, DEFINITIEF!


Houd er rekening mee dat er meer daghandel is en grotere short posities.

Meer LT-beleggers die geduld verliezen en te veel naar de koers kijken zoals TrH. (Maar je moet doen wat je niet laten kunt.)

Moderna, vaccin producent komt ook in november nog met fase 3 resultaten. Is ook een RNA-vaccinproducent net als BioNtech/Pfizer en zal ook wel slagen...!(?)

AstraZeneca / Oxford komt in december met fase 3 resultaten. Problemen lijken daar uit de weggeruimd.

Kunnen allemaal aanleidingen en/of verklaringen zijn voor koersschommelingen. Ik ga proberen een beetje afstand te houden.
Belegger 86
0
Naast de vaccins is er zeker nog de behoefte aan een goed medicijn, voor de mensen die geen vaccin willen o.i.d.
Afwachten is het enige wat we kunnen doen, en wachten duurt altijd lang.
Moet zeggen dat ik bij nog geen enkel aandeel heb gehad dat er bepaald nieuws op de verwachtte tijdlijn kwam.
MisterBlues
0
quote:

Belegger 86 schreef op 12 november 2020 18:41:


Naast de vaccins is er zeker nog de behoefte aan een goed medicijn, voor de mensen die geen vaccin willen o.i.d.
Afwachten is het enige wat we kunnen doen, en wachten duurt altijd lang.
Moet zeggen dat ik bij nog geen enkel aandeel heb gehad dat er bepaald nieuws op de verwachtte tijdlijn kwam.


Zeker. Er komen de laatste dagen zo'n 150.000 besmette mensen per dag bij. De pandemie loopt in de VS nog verder uit de klauwen en Trump heeft zich verstopt in het witte huis. :)

Hier een goede beschrijving waar Relief wordt ingezet straks.

Nice Post from MP:
1. the curve of the pandemic is still in the ascending branch of the curve In 2003, SARS was mainly in Asia and took 1.5 years (i.e. until 2005) to disappear from the picture. So much for next year being better....severe COvid cases will be around for a long time to come

2. use of an approved drug in an intensive care unit.
It is correct that the emergency approval of RLF for the seriously ill Covid cases has been registered. As a treating physician an EUA makes it easier for me to use it in the following way:
-the cumbersome paperwork is eliminated.
-The drug is listed and available at the pharmacy.
-In well-assorted intensive care units it is probably on the shelves.
-If a patient develops a severe form of COVID, then he or she is not (no longer) necessarily required to be ventilated immediately. As we know, the SOC has improved.
-We are waiting longer to intubate. This is simply to reduce the risk of the shear forces on the lung tissue caused by the ventilator as much as possible.
-but the x-ray still shows (early) all the signs of ARDS. RLF is therefore used earlier.

-If I as a doctor have had good experience with the use of RLF in 10 patients with heavy covid, then I will certainly be more generous with the indication for the next 10 patients. So if the patients on the normal ward have already been given Remdesivir/ dexamethasone and then become subject to intensive care, then RLF would be my next choice.
-Since hypotension requiring treatment can occur as NW in RLF, the use of RLF intravenously will be reserved for intensive care units and IMC units.
Reader
0
Dat is een duidelijke tekst, veelbelovend voor rlf-100 als we deze arts mogen geloven.
Bukkes
1
Op de site van Relief staat een update over de trials.
Lijkt me positief allemaal, gaan we de 35 frankjes aantikken vandaag ??
UPUPUPUP
KC 1965
0
Relief, with Partner NeuroRx, Announces Enrollment of 150 Patients in Phase 2b/3 Trial of RLF-100(TM) for Critical COVID-19 with Respiratory Failure
Fri, November 13, 2020, 7:35 AM GMT+1
Observations of rapid recovery on chest x-rays noted and no drug-related Serious Adverse Events reported

Relief also reports exercise of 500 million warrants by main shareholder GEM

GENEVA, SWITZERLAND / ACCESSWIRE / November 13, 2020 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief" or the "Company") with its partner NeuroRx, Inc., announced that as of today, 150 patients (out of a targeted enrollment of 165) have been enrolled in the ongoing phase 2b/3 trial of RLF-100(TM) (aviptadil) for treating respiratory failure in patients with critical COVID-19. Respiratory failure is defined, according to FDA guidance, as the need for intensive care with mechanical ventilation, non-invasive ventilation, or high-flow nasal oxygen in order to sustain adequate levels of blood oxygen. So far, no drug-related serious adverse events have been reported.


There is currently no FDA-approved drug that has shown efficacy in patients who are already in the Intensive Care Unit (ICU) with Respiratory Failure. Although NeuroRx and Relief are optimistic that RLF-100(TM) will also be effective in treating early COVID-19, the companies have focused first on those patients who have no available therapy and are at the highest risk of mortality. An open-label prospective study in patients with Critical COVID-19 has already shown a nine-fold hazard ratio advantage in both survival and recovery from respiratory failure (http://dx.doi.org/10.2139/ssrn.3665228) with both statistically significant (P < .001). More than 110 patients with similar severity have additionally been treated nationwide under an FDA-sanctioned Expanded Access Protocol (NCT04453839).

Although the phase 2b/3 study remains blinded, illustrative blinded recoveries from signs of Critical COVID-19 on Chest x-ray within 10 days have been reported by study sites and shared with the study's Data Monitoring Committee and FDA. Until the study is unblinded, it cannot be known whether this rapid recovery was more frequent among patients treated with RLF-100(TM) compared to those treated with placebo. However, in the open-label prospective study, more rapid recovery was seen among 21 patients treated with RLF-100TM than those treated with standard of care with an average of nine fewer ICU days in the RLF-100TM treated patients compared to those treated with Standard of Care.

Completion of enrollment is anticipated in the coming weeks. Enrollment was uniquely challenged by the devastating effects of the pandemic. It strained the capacity of hospitals and caused the temporary incapacity of investigators and study coordinators at several study sites, who themselves contracted COVID-19 in the course of their duties.

"Should RLF-100(TM) prove to be safe and effective for treating COVID-19 Respiratory Failure, the nation will owe an eternal debt of gratitude to the front-line healthcare workers, technicians, study coordinators, nurses, and doctors who worked seven days a week to help develop this treatment while risking their own health to do so. They are the true heroes," said Prof. Jonathan Javitt, CEO and founder of NeuroRx, Inc.

GEM Exercises Warrants
Relief also reported today that the Company's main shareholder, GEM Global Yield LLC SCS ("GEM"), has exercised 500 million warrants. GEM has 86.66 million warrants remaining in Relief. Following this exercise, Relief's available cash balance totals approximately CHF 49,800,000. Upon issuance of the shares, the total amount of shares outstanding will be 3,160,068,581.
Jaapie23
1
quote:

Bachhaus schreef op 13 november 2020 07:45:


Op de site van Relief staat een update over de trials.
Lijkt me positief allemaal, gaan we de 35 frankjes aantikken vandaag ??
UPUPUPUP


Ik verwacht bij sluiting minimaal 40 frankjes!
DeZwarteRidder
0
GEM Exercises Warrants

Relief also reported today that the Company's main shareholder, GEM Global Yield LLC SCS ("GEM"), has exercised 500 million warrants. GEM has 86.66 million warrants remaining in Relief. Following this exercise, Relief's available cash balance totals approximately CHF 49,800,000.

Upon issuance of the shares, the total amount of shares outstanding will be 3,160,068,581.
DeZwarteRidder
0
quote:

Jaapie23 schreef op 13 november 2020 07:56:


[...]Ik verwacht bij sluiting minimaal 40 frankjes!

Dat zullen wel Belgische frankjes worden.............
KC 1965
0
quote:

DeZwarteRidder schreef op 13 november 2020 07:58:


GEM Exercises Warrants

Relief also reported today that the Company's main shareholder, GEM Global Yield LLC SCS ("GEM"), has exercised 500 million warrants. GEM has 86.66 million warrants remaining in Relief. Following this exercise, Relief's available cash balance totals approximately CHF 49,800,000.

Upon issuance of the shares, the total amount of shares outstanding will be 3,160,068,581.



GEM is 100% sure about RLF otherwise they wil not exercise them .


In finance, a warrant is a security that entitles the holder to buy the underlying stock of the issuing company at a fixed price called exercise price until the expiry date.

Warrants and options are similar in that the two contractual financial instruments allow the holder special rights to buy securities. Both are discretionary and have expiration dates. The word warrant simply means to "endow with the right", which is only slightly different from the meaning of option.

Warrants are frequently attached to bonds or preferred stock as a sweetener, allowing the issuer to pay lower interest rates or dividends. They can be used to enhance the yield of the bond and make them more attractive to potential buyers. Warrants can also be used in private equity deals. Frequently, these warrants are detachable and can be sold independently of the bond or stock.
Jaapie23
0
quote:

KC 1965 schreef op 13 november 2020 08:25:


[...]

GEM is 100% sure about RLF otherwise they wil not exercise them .

For those bashers please read :
In finance, a warrant is a security that entitles the holder to buy the underlying stock of the issuing company at a fixed price called exercise price until the expiry date.

Warrants and options are similar in that the two contractual financial instruments allow the holder special rights to buy securities. Both are discretionary and have expiration dates. The word warrant simply means to "endow with the right", which is only slightly different from the meaning of option.

Warrants are frequently attached to bonds or preferred stock as a sweetener, allowing the issuer to pay lower interest rates or dividends. They can be used to enhance the yield of the bond and make them more attractive to potential buyers. Warrants can also be used in private equity deals. Frequently, these warrants are detachable and can be sold independently of the bond or stock.


Inderdaad, dit gaat GEM een flinke bak geld opleveren.
DeZwarteRidder
0
quote:

Jaapie23 schreef op 13 november 2020 08:29:


[...]Inderdaad, dit gaat GEM een flinke bak geld opleveren.

Alleen als ze op tijd verkopen.

Het risico dat GEM gaat dumpen is weer vele malen groter geworden.

En de maximale koers wordt steeds lager.

Dit nieuws gaat weer een flinke klap naar beneden opleveren.

En Relief is blijkbaar een holle-bolle-Gijs voor geld.
Jaapie23
0
quote:

DeZwarteRidder schreef op 13 november 2020 08:37:


[...]
Alleen als ze op tijd verkopen.

Het risico dat GEM gaat dumpen is weer vele malen groter geworden.

En de maximale koers wordt steeds lager.

Dit nieuws gaat weer een flinke klap naar beneden opleveren.


Ook dan levert het GEM een flinke bank geld op.
Het kan twee kanten op, gezien de röntgenfoto's en het PR zeg ik binnen nu en 2 weken boven de CHF 0,80.

Vanuit jouw rol als "Zwarte Ridder" begrijp ik je opmerking uiteraard.
DeZwarteRidder
1
De emissiekoers is zo vreselijk laag ( 5 cent ofzo) dat GEM bijna onmogelijk verlies kan lijden op deze deal.
7.939 Posts, Pagina: « 1 2 3 4 5 6 ... 215 216 217 218 219 220 221 222 223 224 225 ... 393 394 395 396 397 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 12 mei 2021 17:31
Koers 0,186
Verschil +0,007 (+3,92%)
Hoog 0,188
Laag 0,177
Volume 8.774.096
Volume gemiddeld 18.340.237
Volume gisteren 23.501.594

Brussel real time stocks quotedata by Euronext. Other real time EU stocks, by Cboe Europe Ltd.; US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront